Video

Checkpoint Inhibition Squamous Cell and Nonsquamous Cell NSCLC

Related Videos
Shirish M. Gadgeel, MD
Jacob Sands, MD
Charu Aggarwal, MD, MPH, FASCO
Andrea Wolf, MD, MPH
Nagashree Seetharamu, MD, MBBS
Shirish M. Gadgeel, MD
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Related Content
FDA
September 25th 2024

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Danny Nguyen, MD
September 23rd 2024

BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

The OncFive: Top Oncology Articles for the Week of 9/15
September 21st 2024

The OncFive: Top Oncology Articles for the Week of 9/15

Charnita Zeigler-Johnson, PhD, MPH
Published: September 20th 2024 | Updated: September 20th 2024

Fox Chase Cancer Center Researchers Examine Perceptions of Smoking Stigma Among African American/Black Populations